Empagliflozin vs Rituximab

Empagliflozin vs Rituximab: Overview

This comparison examines the pharmacological differences between Empagliflozin and Rituximab.

Mechanism of Action

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Empagliflozin — 12.4 hours; Rituximab — 22 days.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7.

Molecular Weight: Empagliflozin — 450.9100 g/mol.

Type: Empagliflozin — Small molecule; Rituximab — Antibody.